C. A. Ford

This study shows that wild-type KRAS suppresses tumour growth and metastasis in KRAS mutant colorectal cancer while enhancing resistance to MEK inhibition.

This study shows that loss of wild-type Kras enhances oncogenic Kras signaling and promotes pancreatic ductal adenocarcinoma, while also increasing sensitivity to MEK1/2 inhibitors.

This study uses metabolomics to stratify colorectal cancer tissues and identifies adenosylhomocysteinase as a potential therapeutic target.

This study shows that combining CXCR2 inhibition with anti-PD1 therapy enhances immunotherapy response in NASH-HCC by reprogramming tumor-associated neutrophils.

This study identifies THEM6 as a marker of ADT resistance in prostate cancer, showing its role in lipid homeostasis and stress response, and highlights it as a potential therapeutic target.

This study identifies cyclocreatine as a dual-action inhibitor of prostate cancer by blocking the phosphagen system and increasing S-adenosyl methionine levels.